Rationale and design of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE)Steven Grinspoon, Pamela S. Douglas, Kathleen V. Fitch et al.|American Heart Journal|2019Cited by 153
Effects of pitavastatin and pravastatin on markers of immune activation and arterial inflammation in HIVMabel Toribio, Steven Grinspoon, Kathleen V. Fitch et al.|AIDS|2017Cited by 87
Assessment of Coronary Artery Disease With Computed Tomography Angiography and Inflammatory and Immune Activation Biomarkers Among Adults With HIV Eligible for Primary Cardiovascular PreventionUdo Hoffmann, Robert T. OʼDonnell, Judith S. Currier et al.|JAMA Network Open|2021Cited by 82
Cardiovascular Risk and Health Among People With Human Immunodeficiency Virus (HIV) Eligible for Primary Prevention: Insights From the REPRIEVE TrialPamela S. Douglas, Steven Grinspoon, Triin Umbleja et al.|Clinical Infectious Diseases|2021Cited by 41
Differential Plasma Protein Regulation and Statin Effects in Human Immunodeficiency Virus (HIV)-Infected and Non-HIV-Infected Patients Utilizing a Proteomics ApproachChristopher R. deFilippi, Steven Grinspoon, Mabel Toribio et al.|The Journal of Infectious Diseases|2020Cited by 27